GT Biopharma Reports Second Quarter Fiscal 2022 Financial Results and Business Update
11 août 2022 09h35 HE
|
GT Biopharma, Inc.
Presented preclinical data demonstration second-generation CD19 targeting Tri-specific Killer Engager (TRIKE®) driving robust NK cell function against B cell malignancies at EHA 2022 Congress.GTB-5550...
GT Biopharma Presents Preclinical Data Demonstrating Second-Generation CD19 Targeting Tri-Specific Killer Engager (TriKE®) Driving Robust NK Cell Function Against B Cell Malignancies at EHA 2022 Congress
10 juin 2022 08h00 HE
|
GT Biopharma, Inc.
Ongoing experiments will evaluate the functionality and efficacy of GTB-7550 in vivoFuture studies will also involve assessments of GTB-7550 TriKE efficacy in other hematologic cancers BRISBANE,...
GT Biopharma Reports First Quarter Fiscal 2022 Financial Results and Business Update
16 mai 2022 08h01 HE
|
GT Biopharma, Inc.
Presented pre-clinical data at American Association for Cancer Research (AACR 2022), demonstrating GTB-5550 (cam16-IL15-camB7H3) Tri-specific Killer Engager (TriKE®) driving NK cell activation and...
GT Biopharma to Participate at H.C. Wainwright Hybrid Global Investment Conference
12 mai 2022 08h00 HE
|
GT Biopharma, Inc.
BRISBANE, Calif., May 12, 2022 (GLOBE NEWSWIRE) -- GT Biopharma, Inc. (NASDAQ: GTBP), an immuno-oncology company focused on developing innovative therapeutics based on the Company's proprietary...
GT Biopharma Presents Preclinical Data Demonstrating Novel B7H3+ Tumor Targeting GTB-5550 TriKE® Driving NK Cell Activation and ADCC Against Head and Neck Squamous Cell Carcinomas at AACR Annual Meeting 2022
11 avr. 2022 07h30 HE
|
GT Biopharma, Inc.
- Ongoing experiments will evaluate the functionality and efficacy of the B7H3 TriKE in vivo- Future studies will also involve assessments of the B7H3 TriKE efficacy in the HNSCC tumor...
GT Biopharma Announces Closing of Private Placement Financing and Provides Business Update
06 févr. 2019 16h01 HE
|
GT Biopharma, Inc.
Corporate, preclinical, clinical and regulatory advancements expected to position Company for a transformational 2019 Company on track to report topline Phase 2a data of GTB-1550 this quarter ...
GT Biopharma, Inc. to Present at Biotech Showcase™ 2019
20 déc. 2018 08h22 HE
|
GT Biopharma, Inc.
– Presentation with live audio webcast, Tuesday, January 8, 2019 at 11:30 AM PST – LOS ANGELES, Dec. 20, 2018 (GLOBE NEWSWIRE) -- GT Biopharma, Inc. (OTCQB: GTBP and Euronext Paris GTBP.PA) ("GT...
GT Biopharma Presents Positive Preclinical Data of Tri-specific NK Cell Engager (TriKE) at the 60th American Society of Hematology (ASH) Annual Meeting & Exposition
06 déc. 2018 08h05 HE
|
GT Biopharma, Inc.
– Company’s proprietary TriKE product candidates have the potential to serve as a relatively safe, cost-effective, and easy-to-use therapy for refractory/relapsed AML, high-risk MDS and advanced...
GT Biopharma Announces Presentation of Two Abstracts at the 60th American Society of Hematology (ASH) Annual Meeting & Exposition
20 nov. 2018 07h30 HE
|
GT Biopharma, Inc.
LOS ANGELES, Nov. 20, 2018 (GLOBE NEWSWIRE) -- GT Biopharma, Inc. (OTCQB: GTBP and Euronext Paris GTBP.PA) ("GT Biopharma" or the "Company"), an immuno-oncology biotechnology company focused on...
GT Biopharma Reports Third Quarter 2018 Financial Results and Provides Business Update
15 nov. 2018 08h00 HE
|
GT Biopharma, Inc.
– Recent corporate, preclinical, clinical and regulatory advancements expected to position Company for a transformational 2019 – – FDA clearance of IND to advance first-in-class TriKE, GTB-3550, into...